Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution. As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels. James O’Brien, Vice President Life Sciences at Leica Microsystems, said: “Instead of spending time validating antibodies, the pre-validated […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
